Armstrong Henry H Associates Inc Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Armstrong Henry H Associates Inc reduced its stake in Abbott Laboratories by 0.92% during the most recent quarter end. The investment management company now holds a total of 32,421 shares of Abbott Laboratories which is valued at $1,415,825 after selling 300 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Abbott Laboratories makes up approximately 0.27% of Armstrong Henry H Associates Inc’s portfolio.

Other Hedge Funds, Including , Calamos Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 54 additional shares and now holds a total of 312,118 shares of Abbott Laboratories which is valued at $13,630,193. Abbott Laboratories makes up approx 0.12% of Calamos Advisors’s portfolio.D. Scott Neal boosted its stake in ABT in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 599 shares of Abbott Laboratories which is valued at $25,547. Abbott Laboratories makes up approx 0.02% of D. Scott Neal’s portfolio.Regent Investment Management boosted its stake in ABT in the latest quarter, The investment management firm added 4,194 additional shares and now holds a total of 11,678 shares of Abbott Laboratories which is valued at $491,527. Abbott Laboratories makes up approx 0.26% of Regent Investment Management’s portfolio.Physicians Financial Services boosted its stake in ABT in the latest quarter, The investment management firm added 266 additional shares and now holds a total of 6,897 shares of Abbott Laboratories which is valued at $290,295. Abbott Laboratories makes up approx 0.25% of Physicians Financial Services’s portfolio.Washington Trust Bank boosted its stake in ABT in the latest quarter, The investment management firm added 386 additional shares and now holds a total of 7,872 shares of Abbott Laboratories which is valued at $329,758. Abbott Laboratories makes up approx 0.08% of Washington Trust Bank’s portfolio.

Abbott Laboratories opened for trading at $44.38 and hit $45.12 on the upside on Friday, eventually ending the session at $44.75, with a gain of 0.67% or 0.3 points. The heightened volatility saw the trading volume jump to 1,34,23,155 shares. Company has a market cap of $65,745 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *